Felix receives a significant minority share from Advent
In a significant move, leading global private equity investor Advent International has announced the acquisition of a significant minority stake in Felix Pharmaceuticals Pvt Ltd, a prominent player in the Gx animal pharma sector.
The deal, detailed on the Advent website, was advised by a multidisciplinary team from the law firm Arthur Cox. The team included experts in Corporate and M&A, Tax, Competition and Regulated Markets, and Life Sciences.
Tim Gleeson, Daire Cassidy, Glyn McCormack, and Sondos Sididiqi represented the Corporate and M&A division, while David Kilty and Nicola Cavey were part of the Tax division. Simon Breen and Robert Byrne were members of the team in the Competition and Regulated Markets division, and Colin Kavanagh was part of the Life Sciences division.
Although JSA advised Felix Pharmaceuticals for this deal, no Advent-specific advisors from their side are explicitly mentioned in the available sources. However, Advent International has recently appointed Robert Ohrenstein as a Finance and Operations Advisor, who brings deep private equity financial expertise and may provide advisory support in operations and financial matters for Advent’s portfolio companies. It is not explicitly stated that Ohrenstein advised on the Felix Pharmaceuticals deal.
Michael Coyle led the team from Advent International for this transaction. The acquisition marks a strategic move for Advent, expanding their portfolio in the animal healthcare sector. Felix Pharmaceuticals, a leading global player in Gx animal pharma, is expected to contribute significantly to Advent's growth in this domain.
The exact financial details of the deal have not been disclosed. Nonetheless, the acquisition underscores Advent International's commitment to investing in innovative and growing companies across various sectors. As the company continues to expand its footprint, it is poised to make a significant impact in the global animal healthcare market.
- Robert Ohrenstein, appointed as a Finance and Operations Advisor at Advent International, brings deep private equity financial expertise and may provide advisory support in operations and financial matters for Advent's portfolio companies, expanding their team's knowledge in finance.
- Advent International's recent acquisition of a significant minority stake in Felix Pharmaceuticals, a prominent player in the Gx animal pharma sector, is a strategic move that underscores their commitment to investing in innovative and growing companies in the finance sector, specifically in the animal healthcare domain.
